Oxandrolone treatment of short stature: Effect on predicted mature height

Bettmann, Hilda K.; Goldman, Harold S.; Abramowicz, Mark; Sobel, Edna H.

doi:10.1016/s0022-3476(71)80204-4

Cited by 40 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, trends in the comparison of the groups’ height velocity increment did not become statistically significant. Growth acceleration is comparable to previous reports on the use of testosterone [3, 4]or oxandrolone [5, 6, 7, 8, 9, 10]in CDG. Along with comparable growth, gonadarche advanced faster in the testosterone-50-mg group than in the oxandrolone group.…”

Section: Discussionsupporting

confidence: 87%

“…This advance was significantly greater than that of the oxandrolone group. In the latter, bone maturation advanced by a mean 1 ‘year’ for each chronological year, as previously reported [6, 7, 9]. Appropriate-for-age bone maturation is distinctive for such therapy during adolescence of CDG children, as utilized in the present protocol, when the tempo of bone maturation is expected to be faster.…”

Section: Discussionsupporting

confidence: 69%

“…In both studies the final height was comparable to the pretreatment height prediction and it was concluded that this was an effective treatment for short-term acceleration of growth and that final adult height is neither compromised nor is it advanced. The oral administration of daily oxandrolone produced likewise positive short-term results and no long-term effects or change in final height, as reported from several studies, old and new [6, 7, 8, 9, 10, 11]. An inherent problem in that type of reports is the multiple variables of age, dose and period of treatment, which make the comparison of treatment modalities difficult, unless they are delivered under the same protocol.…”

Section: Introductionmentioning

confidence: 69%

“…As the theoretical comparable dose of testosterone propionate-enanthate (estimated potency ratio oxandrolone/testosterone = 6.3) [11]was smaller than the traditional 50 mg/kg/month, we added a low dose testosterone group, receiving 25 mg/kg/month. Based on previous reports of no response to placebo [7, 10], such control group was considered redundant and unethical.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Androgen Therapy in Constitutional Delay of Growth

Lampit

Hochberg

2003

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aims: Two modalities of androgen therapy prevail in the treatment of constitutional delay of growth (CDG): monthly injections of testosterone or daily tablets of the non-aromatizable oxandrolone. The present study was undertaken to prospectively compare both compounds and dose. Methods: Thirty patients with CDG were the subjects of this study. The protocol required that they all be at age 12–14 years with a bone age delay of more than 2 ‘years’, height less than –2 SDS and growth velocity less than –0.5 SDS. The subjects were at a Tanner stage 1 or 2 and testicular volume were no larger than 4 ml. They were randomly assigned into 3 treatment groups: group 1 patients received monthly injections of 25 mg testosterone propionate-enanthate; group 2 patients received monthly injections of 50 mg testosterone propionate-enanthate; group 3 patients received oral oxandrolone at a weekly dose of 0.7 mg/kg. Treatment was given for a period of 6 months and follow-up commenced 6 months later and yearly thereafter for 2 years. Results: Height velocity and height increased significantly only in groups 2 and 3. Bone age advanced most in group 2. Puberty progressed faster in that group as compared with group 3. The predicted adult height before and 2 years after completion of treatment remained unchanged in the two testosterone groups. It increased significantly in the oxandrolone group from a mean 169.8 cm before therapy to a mean 177.5 cm 2 years after completion of therapy. Peak GH levels were significantly higher on both testosterone 50 mg and oxandrolone, as compared to pretreatment levels. The increment was significantly greater in group 2 as was the increment in serum IGF-1 and IGFBP3. Conclusions: These results imply that 6 months of testosterone injections at a dose of 50 mg, but not 25 mg, is an effective and safe treatment for patients with CDG, with no considerable impact on final height prediction. On the other hand, daily oxandrolone treatment, starting at age 12–14 years, may increase the predicted final adult height.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 69%

Section: Introductionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Androgen Therapy in Constitutional Delay of Growth

Lampit

Hochberg

2003

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Oxandrolone is thought to be a safe compound because of its low androgenic activity. In preschool children, the duration of the treatment is usually 6 months [3, 12], but even in treatment periods between 3 and 60 months, no side effects were noticed [8, 13, 14, 15]. It is not reported that oral androgens have caused the pulsatile secretory mode to advance to more mature levels in constitutionally delayed boys [7].…”

Section: Discussionmentioning

confidence: 99%

Induction of Early Puberty in a Boy after Treatment with Oxandrolone?

Doeker¹,

Müller-Michaels²,

Andler³

1998

Horm Res Paediatr

View full text Add to dashboard Cite

We report on a 9-year-old boy with early puberty who had been treated with oxandrolone because of constitutional delay of growth. Treatment was started at the age of 6.25 years. During the treatment with oxandrolone over 22 months, the height velocity increased above the 97th percentile, and bone age developed twice as fast as chronological age. After discontinuing the medication, the growth velocity did not decrease, and the bone age still accelerated. When he was 9.1 years old, testicular volume had increased to 12 ml, pubic hair stage had progressed and he developed a mild facial acne. We hypothesize that oxandrolone could have induced an early onset of puberty in this boy. We conclude that treatment with oxandrolone in young children should be considered carefully and be used for short periods only. Potential side effects might include the rapid acceleration of puberty and skeletal maturation.

show abstract

Use of Oxandrolone for Growth Stimulation in Children

Jackson¹

1973

Arch Pediatr Adolesc Med

View full text Add to dashboard Cite

Oxandrolone treatment of short stature: Effect on predicted mature height

Cited by 40 publications

References 17 publications

Androgen Therapy in Constitutional Delay of Growth

Androgen Therapy in Constitutional Delay of Growth

Induction of Early Puberty in a Boy after Treatment with Oxandrolone?

Use of Oxandrolone for Growth Stimulation in Children

Contact Info

Product

Resources

About